Teva Pharmaceutical Industries (TEVA) Given New $16.00 Price Target at Leerink Swann

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price dropped by stock analysts at Leerink Swann from $17.00 to $16.00 in a research report issued on Friday. The brokerage presently has an “underperform” rating on the stock. Leerink Swann’s price target suggests a potential downside of 11.16% from the company’s current price.

Several other research firms have also weighed in on TEVA. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Vetr lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price objective on the stock. in a research note on Thursday, January 11th. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $24.00 price objective on the stock. in a research note on Thursday, January 18th. They noted that the move was a valuation call. Finally, Credit Suisse Group set a $20.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday, January 22nd. Nine analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average price target of $21.61.

Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.63 during mid-day trading on Friday, hitting $18.01. 4,960,350 shares of the stock were exchanged, compared to its average volume of 19,598,504. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $37.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market capitalization of $18,840.00, a price-to-earnings ratio of -3.07, a P/E/G ratio of 1.51 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.17. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. The firm’s revenue was down 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 earnings per share. equities research analysts predict that Teva Pharmaceutical Industries will post 3.73 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. Calton & Associates Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $108,000. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $129,000. Fieldpoint Private Securities LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $171,000. Global Financial Private Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $193,000. Finally, Sigma Planning Corp bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $214,000. 51.99% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Given New $16.00 Price Target at Leerink Swann” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2018/02/09/teva-pharmaceutical-industries-teva-given-new-16-00-price-target-at-leerink-swann.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply